4.7 Article

In vivo evolution of drug-resistant Mycobacterium tuberculosis in patients during long-term treatment

期刊

BMC GENOMICS
卷 19, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/s12864-018-5010-5

关键词

Drug-resistant tuberculosis; Treatment; Genetic changes; SNP

资金

  1. Key Project Specialized for Infectious Diseases of the Chinese Ministry of Health [2013ZX10003009]
  2. Tongzhou District Science and Technology Committee [KJ2017CX053]
  3. National Natural Science Foundation of China (NSFC) [31601081, 81871691]

向作者/读者索取更多资源

Background: In the current scenario, the drug-resistant tuberculosis is a significant challenge in the control of tuberculosis worldwide. In order to investigate the in vivo evolution of drug-resistant M. tuberculosis, the present study envisaged sequencing of the draft genomes of 18 serial isolates from four pre-extensively drug-resistant (pre-XDR) tuberculosis patients for continuous genetic alterations. Results: All of the isolates harbored single nucleotide polymorphisms (SNPs) ranging from 1303 to 1309 with M. tuberculosis H37Rv as the reference. SNPs ranged from 0 to 12 within patients. The evolution rates were higher than the reported SNPs of 0.5 in the four patients. All the isolates exhibited mutations at sites of known drug targets, while some contained mutations in uncertain drug targets including folC, proZ, and pyrG. The compensatory substitutions for rescuing these deleterious mutations during evolution were only found in RpoC I491T in one patient. Many loci with microheterogeneity showed transient mutations in different isolates. Ninety three SNPs exhibited significant association with refractory pre-XDR TB isolates. Conclusions: Our results showed evolutionary changes in the serial genetic characteristics of the pre-XDR TB patients due to accumulation of the fixed drug-resistant related mutations, and the transient mutations under continuous antibiotics pressure over several years.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据